PANDAA universal test for Crimean-Congo hemorrhagic fever (CCHFV)
Official title: PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus.
Funded at Aldatu Biosciences, INC. · NIH-11393717 · Data updated 2026-11-12
A new rapid diagnostic test aims to detect all lineages of Crimean-Congo hemorrhagic fever virus to help people with fever symptoms get timely answers and care.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aldatu Biosciences, INC. NIH-funded |
| Lab location | 1 site (Watertown, UNITED STATES) |
| Project start | March 24, 2021 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $960,045 |
| NIH project number | 5R44AI157650-05 |
| Project ID | NIH-11393717 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with suspected Crimean-Congo hemorrhagic fever or undifferentiated febrile illness in regions where CCHFV is present.
✕Less likely to help
Patients without suspected CCHFV infection or those in areas without access to the test may not benefit.
What this research studies
This project builds a universal molecular test (PANDAA CCHFV) that can identify diverse CCHFV strains in patients across different regions. It uses probe-based qPCR to overcome viral genetic variation, enabling earlier and more reliable diagnosis. The work focuses on expanding access to accurate tests in settings where CCHF is common and where quick decisions can save lives.
Why it matters
Potential benefit: If successful, patients with fever in at-risk areas could receive faster and more accurate diagnoses, guiding timely treatment and isolation decisions.
How similar studies have gone: Previous work showed PANDAA technology can adapt to viral diversity, with ongoing development toward a pan-lineage diagnostic.
Where this research is happening
-
Aldatu Biosciences, INC.
Watertown, United States Active
Researchers
- Principal investigator: Macleod, Iain James — Aldatu Biosciences, INC.
- Study coordinator: Macleod, Iain James
Related research
Other NIH-funded projects on the same topics.
-
Broad antiviral drugs that target coronaviruses and other viruses
A research program aims to identify small molecules that can block multiple viruses, focusing first on coronaviruses, to help create drugs that can treat future outbreaks.
-
Finding broadly protective antibodies against Crimean-Congo Hemorrhagic Fever
Researchers will study blood from people who survived CCHF to find human antibodies that protect against multiple virus variants, with early tests in animal models to check their breadth.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
A New Model for Valley Fever: Studying Coccidioides Infection with Volatile Clues in Wax Moths
Researchers are testing a new, cheaper model using wax moths to study Valley Fever caused by Coccidioides, with the goal of understanding how the infection behaves and how it could be diagnosed or treated.
-
Halogen-modified nucleoside analogs to fight yellow fever virus
Aims to develop new oral medicines that could prevent or treat yellow fever by using specially modified building blocks that stop the virus from growing.
-
Understanding Guanarito virus and building countermeasures for Venezuelan hemorrhagic fever
This project studies how Guanarito virus causes disease and aims to develop vaccines or treatments to protect people in areas where Venezuelan hemorrhagic fever occurs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.